



**LEXOGEN**

The RNA Experts



**QUANT<sup>TM</sup>**  
**SEQ**

Sequencing that counts

# BC1 Block Module for QuantSeq User Guide

Catalog Number:  
167 (RS-BC1 Block)

167UG346V0102

## **FOR RESEARCH USE ONLY. NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE.**

INFORMATION IN THIS DOCUMENT IS SUBJECT TO CHANGE WITHOUT NOTICE.

Lexogen does not assume any responsibility for errors that may appear in this document.

### **PATENTS AND TRADEMARKS**

The QuantSeq 3' mRNA-Seq Library Prep Kits are covered by issued and/or pending patents. QuantSeq™, Kangaroo™, and SIRV™ are trademarks of Lexogen. The SIRVs are covered by issued and/or pending patents. Lexogen UDI 12 nt Unique Dual Index design and UDI sequences are covered by issued and/or pending patents. Lexogen is a registered trademark (EU, CH, US, CN, AU, NO, BR). Illumina® is a registered trademark of Illumina, Inc.; RNasin® is a registered trademark of Promega Corporation. Bioanalyzer®, Fragment Analyzer™, and TapeStation® are trademarks of Agilent Technologies, Inc.; SYBR® Green I is a registered trademark of Molecular Probes, Inc.; LabChip® GX II is a registered trademark of Perkin Elmer. RNaseZap™, RNAlater®, and ERCC are registered trademarks of Ambion, Inc.; Thermomix® is a registered trademark of Eppendorf AG. Qubit™ and NanoDrop™ are registered trademarks of Thermo Fisher Scientific. All other brands and names contained in this user guide are the property of their respective owners. Lexogen does not assume responsibility for patent infringements or violations that may occur with the use of its products.

### **LIABILITY AND LIMITED USE LABEL LICENSE: FOR RESEARCH USE ONLY**

This document is proprietary to Lexogen. The QuantSeq kits are intended for use in research and development only. They need to be handled by qualified and experienced personnel to ensure safety and proper use. Lexogen does not assume liability for any damage caused by the improper use or the failure to read and explicitly follow this user guide. Furthermore, Lexogen does not assume warranty for merchantability or suitability of the product for a particular purpose.

The purchase of the product is subject to Lexogen general terms and conditions ([www.lexogen.com/terms-and-conditions/](http://www.lexogen.com/terms-and-conditions/)) and does not convey the rights to resell, distribute, further sub-license, repackage, or modify the product or any of its components. This document and its content shall not be used or distributed for any other purpose and/or otherwise communicated, disclosed, or reproduced in any way without the prior written consent of Lexogen.

For information on purchasing additional rights or a license for use other than research, please contact Lexogen.

### **WARRANTY**

Lexogen is committed to providing excellent products. Lexogen warrants that the product performs to the standards described in this user guide up to the expiration date. Should this product fail to meet these standards due to any reason other than misuse, improper handling, or storage, Lexogen will replace the product free of charge or issue a credit for the purchase price. Lexogen does not provide any warranty if product components are replaced with substitutes.

Under no circumstances shall the liability of this warranty exceed the purchase price of this product.

We reserve the right to change, alter, or modify any product without notice to enhance its performance.

### **LITERATURE CITATION**

For any publication using this product, please refer to it as Lexogen's QuantSeq™ 3' mRNA-Seq V2 Library Prep Kit FWD or REV with BC1 Block Module.

### **CONTACT INFORMATION**

---

#### **Lexogen GmbH**

Campus Vienna Biocenter 5

1030 Vienna, Austria

[www.lexogen.com](http://www.lexogen.com)

E-mail: [support@lexogen.com](mailto:support@lexogen.com)

#### **Support**

E-mail: [support@lexogen.com](mailto:support@lexogen.com)

Tel. +43 (0) 1 3451212-41

Fax. +43 (0) 1 3451212-99

# Table of Contents

1. Overview. . . . .	4
2. Kit Components and Storage Conditions . . . . .	6
3. Protocol . . . . .	7
4. Appendix A: Input RNA and PCR Cycles. . . . .	8
5. Appendix B: Revision History. . . . .	10

# 1. Overview

This User Guide outlines the protocol for using the BC1 Block Module for QuantSeq, with the QuantSeq 3' mRNA-Seq V2 Library Prep Kits FWD and REV. QuantSeq uses total RNA as input with oligo(dT) priming to generate first strand cDNA. RNA removal is then performed and second strand synthesis is initiated by random priming. Final library amplification by PCR adds complete Illumina-compatible sequencing adapters and unique indices. For more detailed information about these protocols, please refer to the complete QuantSeq 3' mRNA-Seq User Guide available at [www.lexogen.com/docs/quantseq](http://www.lexogen.com/docs/quantseq).

Lexogen's BC1 Block Module blocks the generation of library fragments from abundant BC1 transcripts that are present in mouse brain samples (*Mus musculus*, Mm). The BC1 Block Module consists of a modified RNA Removal Solution containing transcript-specific oligos complementary to these highly abundant BC1 lncRNAs.

The Removal Solution-BC1 Block (**RS-BC1B●**) replaces the standard RNA Removal Solution (**RS○**) at the RNA removal step of the QuantSeq 3' mRNA-Seq Library Prep protocol. The oligos bind to the BC1 first strand cDNA and prevent the generation of amplifiable library fragments from BC1 lncRNAs during second strand synthesis (see Fig. 1).

The BC1 Block Module is provided for 96 reactions and can only be used with the QuantSeq 3' mRNA-Seq Library Prep Kits from Lexogen (FWD and REV).




Figure 1. Schematic overview of the QuantSeq workflow using the BC1 Block Module for BC1 depletion. *Mus musculus* (Mm) brain total RNA contains a mixture of both BC1 and non-BC1 mRNAs, which are both reverse transcribed by oligo(dT) priming during first strand synthesis. If RS-BC1 Block (RS-BC1B ●) solution is added instead of the standard RNA Removal Solution (RS ○), the BC1 Blocker oligos bind specifically to BC1 first strand cDNA and block BC1 second strand cDNA synthesis. After second strand synthesis, the sample will contain both non-amplifiable BC1 cDNA fragments and tagged double-stranded cDNA library fragments for non-BC1 mRNAs. During PCR, only the non-BC1 library fragments are amplified to add full-length adapters and indices for Illumina sequencing.

## 2. Kit Components and Storage Conditions

BC1 Block Module (-20 °C)




Figure 2. Location of kit components.

RS-BC1 Block, 96 rxn (Cat. No. 167)	Tube Label	Volume*	Storage
		96 rxn	
Removal Solution-BC1 Block	RS-BC1B ●	528 µl	 -20 °C

\*including ≥10 % surplus

**ATTENTION:** Upon receipt the solution should be stored in a -20 °C freezer.

**NOTE:** The BC1 Block Module for QuantSeq is not a stand-alone kit. It is an Add-on Module for the QuantSeq FWD and REV kits and requires the components therein for functionality. The Removal Solution-BC1 Block (RS-BC1B ●) replaces the standard RNA Removal Solution (RS ○) at the RNA removal step of the standard QuantSeq 3' mRNA-Seq Library Prep protocol.

**NOTE:** For user-supplied consumables and equipment needs, please refer to the appropriate QuantSeq 3' mRNA-Seq V2 Library Prep Kit User Guides.

# 3. Protocol

**ATTENTION:** QuantSeq generated first strand cDNA (FWD and REV) is required as input for RNA removal using the Removal Solution-BC1 Block (**RS-BC1B ●**). BC1 blocker oligos hybridize specifically to BC1 first strand cDNA and block the extension of second strand cDNA in subsequent library preparation steps. This results in non-amplifiable, single-stranded BC1 cDNA fragments.

## RNA Removal - BC1 Block

During this step the RNA template is degraded, which is essential for efficient second strand synthesis, and BC1 blockers are added. Before removing the sealing foil after the first strand synthesis reaction, quickly spin down the plate to make sure all liquid is collected at the bottom of the wells.

**ATTENTION:** The Removal Solution-BC1 Block (**RS-BC1B ●**) replaces the RNA Removal Solution (**RS ○**) from the QuantSeq 3' mRNA-Seq V2 Library Prep Kits.

**NOTE:** RS-BC1 Block (**RS-BC1B ●**) should be used for mouse brain RNA samples.



First Strand cDNA Synthesis is carried out according to the QuantSeq User Guides (191UG444 or 225UG675) steps 1 to 4.

---

5

Add 5  $\mu$ l of Removal Solution-BC1 Block (**RS-BC1B ●**) directly to the first strand cDNA synthesis reaction. Mix well, reseal the plate using a fresh foil, and spin down. **REMARK:** Use a pipette set to 15  $\mu$ l for efficient mixing.

---

6

Incubate for 10 minutes at 95 °C, then cool down to 25 °C. Spin down the plate at room temperature and carefully remove the sealing foil.

---



Proceed to Second Strand Synthesis (step 7) as described in the QuantSeq User Guides (191UG444 or 225UG675).

---

## 4. Appendix A: Input RNA and PCR Cycles

Total RNA from mouse brain is the intended input for QuantSeq library preps using RS-BC1 Block Module for BC1 depletion. No prior depletion of BC1 lncRNA, poly(A) enrichment, or ribosomal RNA is required. The minimum recommended input for this protocol is 10 ng of total RNA (RIN  $\geq 6$ ). It is important to ensure that total RNA is of high purity: Ideal values for A260/280 and A260/230 absorbance ratios should be 1.8 - 2.1, and approximately 2, respectively. For low quality RNA samples, please follow the protocol modification listed at the bottom of the page.

We recommend the use of Lexogen's SPLIT RNA Extraction Kit for isolation of total RNA. The table below shows an example of PCR cycle numbers used for input amounts of mouse total RNA from brain samples.

Species	Sample Type	Input Amount	PCR Cycles	
			Undepleted	+ RS-BC1 Block
Mouse	Brain	500 ng	13	13
		50 ng	16	16
		10 ng	19	20

BC1 lncRNAs constitute >34 % of the total mRNA pool. Therefore, when blocking these lncRNAs from the final step of library generation, the cycle numbers may need to be increased to achieve the same library yield as non-depleted samples. Adding one additional PCR cycle compared to non-depleted blood samples is typically sufficient. However, as the mRNA content, purity, and quality of total RNA from brain samples may vary depending on the origin of the sample, **we strongly recommend performing the qPCR assay to determine the optimal number of cycles for the library amplification** (see the respective Appendix in the QuantSeq User Guides (191UG444 or 225UG675)).

**ATTENTION:** For low quality RNA we recommend: skipping step 2, reducing the amount of PS added in step 16 (48  $\mu$ l instead of 56  $\mu$ l), and reducing the amount of PB in step 29 (31.5  $\mu$ l PB instead of 35  $\mu$ l PB for dual indexed libraries and 27  $\mu$ l PB instead of 30  $\mu$ l PB for single indexed libraries, respectively). For information regarding the use of input amounts <10 ng please contact [support@lexogen.com](mailto:support@lexogen.com), or see the QuantSeq online FAQs at [www.lexogen.com](http://www.lexogen.com).

## Typical Results

Figures 3 and 4 show examples of QuantSeq libraries prepared from mouse brain samples with and without the Removal Solution-BC1 Block (RS-BC1B ●). Distinct peaks in bioanalyzer traces between 230 and 280 bp, which correspond to abundant BC1 lncRNA library fragments, are present in standard libraries but are no longer present in **RS-BC1B ●** libraries.




Figure 3. Bioanalyzer traces for mouse QuantSeq FWD libraries prepared with and without the RS-BC1 Block solution (RS-BC1B, Cat. No. 167). Libraries were prepared from 50 ng of mouse brain RNA with the Standard QuantSeq FWD protocol (RS Standard, red trace), versus QuantSeq with BC1 Block (+RS-BC1B, blue trace). Commercially available mouse brain RNA (BioCat MR-201) was used. Both libraries were amplified with 16 cycles. The two dominant peaks between 230 and 280 bp that are visible in the standard libraries are no longer visible after BC1 blocking.




Figure 4. Bioanalyzer traces for mouse QuantSeq FWD libraries prepared with and without the RS-BC1 Block solution (RS-BC1B, Cat. No. 167). Libraries were prepared from 10 ng of mouse brain RNA with the Standard QuantSeq FWD protocol (RS Standard, red trace), versus QuantSeq with BC1 Block (+RS-BC1B, blue trace). RNA was isolated using the SPLIT RNA Extraction Kit (Lexogen). Both libraries were amplified with 20 cycles. Dominant BC1 peaks that are visible in the standard libraries are no longer visible after BC1 blocking.

## Overcycling

A peak in high molecular weight regions (between 1,000 - 9,000 bp) is an indication of overcycling. This could occur if cycle numbers are increased too much to compensate for lower input material. Prevent overcycling by using the qPCR assay as described in the respective Appendix of the QuantSeq User Guides (191UG444 or 225UG675).

## 5. Appendix B: Revision History

Publication No. / Revision Date	Change	Page
167UG346V0102 Jul. 22, 2024	Update according to QuantSeq V2 release (FWD and REV). Remove references to Cat. No. 020 and 080. Include references to Cat. No. 208.	All
167UG346V0101 Jan. 25, 2023	Updated Kit Components Figure 2 and Table to reflect current packaging and storage requirements.	6
167UG346V0100 May 19, 2021	Initial Release.	

Associated Products:

- 008 (SPLIT RNA Extraction Kit)
- 022 (Purification Module with Magnetic Beads)
- 025, 050, 051, 141 (SIRVs Spike-in RNA Variant Control Mixes)
- 081 (UMI Second Strand Synthesis Module for QuantSeq FWD (Illumina, Read 1))
- 191 - 196 (QuantSeq 3' mRNA-Seq V2 Library Prep Kit FWD with UDI)
- 208 (PCR Add-on and Reamplification Kit V2 for Illumina)
- 225 (QuantSeq 3' mRNA-Seq V2 Library Prep Kit REV with Custom Sequencing Primer and UDI Set B1)

## BC1 Block Module for QuantSeq · User Guide

Lexogen GmbH  
Campus Vienna Biocenter 5  
1030 Vienna, Austria  
Telephone: +43 (0) 1 345 1212-41  
Fax: +43 (0) 1 345 1212-99  
E-mail: [support@lexogen.com](mailto:support@lexogen.com)  
© Lexogen GmbH, 2024

Lexogen, Inc.  
51 Autumn Pond Park  
Greenland, NH 03840, USA  
Telephone: +1-603-431-4300  
Fax: +1-603-431-4333  
[www.lexogen.com](http://www.lexogen.com)